Long term results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomized, phase 3, equivalence trial. Lancet 2019; 394: 2155-2164

Published: 5th March 2020

Authors: Vicini FA, Cecchini RS, White JR, Arthur DW, Julian TB, Rabinovitch RA et al.

Conclusion

This study included 4216 women with a median follow-up of 10.2 years. Ipsilateral breast cancer recurrence was four per cent after partial, and three per cent after whole breast irradiation: hazard ratio 1.22, 95 per cent confidence interval 0.94 to 1.58.

You may also be interested in

Scientific Surgery

Concurrent neoadjuvant chemotherapy and estrogen deprivation in patients with estrogen receptor–positive, human epidermal growth factor receptor 2–negative breast cancer (CBCSG‐036): A randomized, controlled, multicenter trial. Cancer 2019; 125: 2185-2193

Authors: Yu K-D, Wu S-Y, Liu G-Y, Wu J, Di G-H, Hu Z et al.

Scientific Surgery

West German Study Plan B Trial: adjuvant four cycles of epirubicin and cyclophosphamide plus docetaxel versus six cycles of docetaxel and cyclophosphamide in HER2-negative early breast cancer. J Clin Oncol 2019; 37: 799-808

Authors: Nitz M, Gluz O, Clemens M, Malter W, Reimer T, Nuding B et al.

Scientific Surgery

Pembrolizumab for early triple-negative breast cancer. N Engl J Med 2020; 382: 810-821

Authors: Schmid P, Cortes J, Pusztai L, McArthur H, Kummel S, Bergh J et al.

Scientific Surgery

External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node negative breast cancer (RAPID): a randomized controlled trial. Lancet 2019; 394: 2165-2172

Authors: Whelan TJ, Julian JA, Berrang TS, Kim D-H, Germain I, Nichol AM et al.

Scientific Surgery

Use of anastrozole for breast cancer prevention (IBIS-II): long term results of a randomized controlled trial. Lancet 2020; 395: 117-122

Authors: Cuzik J, Sestak I, Forbes JF, Dowsett M, Cawthorn S, Mansel RE et al.

Scientific Surgery

Randomized phase II study evaluating palbociclib in addition to letrozole as neoadjuvant therapy in estrogen receptor–positive early breast cancer: PALLET trial. J Clin Oncol 2019; 37: 178-189.

Authors: Johnston S, Puhalla S, Wheatley D, Ring A, Barry P, Holcombe C et al.

Scientific Surgery

Adjuvant letrozole and tamoxifen alone or sequentially for postmenopausal women with hormone receptor–positive breast cancer: long-term follow-up of the BIG 1-98 Trial. J Clin Oncol 2019; 37: 105-114.

Authors: Ruhstaller T, Giobbie-Hurder A, Colleoni M, Jensen M-B, Ejlertson B, de Azambuja E et al.

Scientific Surgery

Six versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. Lancet 2019; 393: 2599–2612.

Authors: Earl HM, Hiller L, Vallier A-L, Loi S, McAdam K, Hughes-Davies L et al.

Scientific Surgery

Six months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial. Lancet 2019; 393: 2591-2598.

Authors: Pivot X, Romieu G, Debled M, Pierga J-Y, Kerbrat P, Bachelot T et al.

Scientific Surgery

Subcutaneous vs intravenous trastuzumab for patients with ERBB2-positive early breast cancer: final analysis of the HannaH Phase 3 randomized clinical trial. JAMA Oncol 2019; 5:e190339.

Authors: Jackisch C, Stroyakovskiy D, Pivot X, Ahn JS, Melichar B, Chen SC et al.

Scientific Surgery

Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. Lancet 2019; 393: 1440-1452.

Authors: Early Breast Cancer Trialists' Collaborative Group (EBCTCG)

Scientific Surgery

Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med 2019; 380: 617-628.

Authors: Von Minckwitz G, Huang C-S, Mano MS, Loibl S, Mamounas EP, Untch M et al.